GlassScriptPhysician profile
Alexa N Byrd
NPI 1437813268
$2,167.12
in general payments reported to CMS, 2019-2025
17 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $603 · 2023: $170 · 2024: $614 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $342.52 | 2023-2025 | Jemperli, Ojjaara, Zejula |
| Amgen INC. | $274.87 | 2021-2022 | |
| Janssen Biotech, INC. | $168.40 | 2022-2025 | Erleada, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $149.36 | 2022-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $135.63 | 2024 | Lynparza |
| Blueprint Medicines Corporation | $133.70 | 2022 | |
| Puma Biotechnology, INC. | $106.09 | 2022 | |
| Daiichi Sankyo INC. | $69.36 | 2025 | Datroway, Enhertu |
| Merck Sharp & Dohme LLC | $68.64 | 2023-2025 | Keytruda |
| Stemline Therapeutics INC. | $54.54 | 2023 | Orserdu |
| Novartis Pharmaceuticals Corporation | $35.42 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $30.93 | 2021 | |
| Geron Corporation | $24.73 | 2025 | Rytelo |
| Incyte Corporation | $18.17 | 2025 | Jakafi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $17.55 | 2025 | |
| Eisai INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.